CN114533701B - 一种马钱子碱凝胶贴膏剂及其制备方法和用途 - Google Patents
一种马钱子碱凝胶贴膏剂及其制备方法和用途 Download PDFInfo
- Publication number
- CN114533701B CN114533701B CN202111376621.6A CN202111376621A CN114533701B CN 114533701 B CN114533701 B CN 114533701B CN 202111376621 A CN202111376621 A CN 202111376621A CN 114533701 B CN114533701 B CN 114533701B
- Authority
- CN
- China
- Prior art keywords
- strychnine
- gel
- paste
- organic phase
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- QMGVPVSNSZLJIA-FVWCLLPLSA-N strychnine Chemical compound O([C@H]1CC(N([C@H]2[C@H]1[C@H]1C3)C=4C5=CC=CC=4)=O)CC=C1CN1[C@@H]3[C@]25CC1 QMGVPVSNSZLJIA-FVWCLLPLSA-N 0.000 title claims abstract description 266
- QMGVPVSNSZLJIA-UHFFFAOYSA-N Nux Vomica Natural products C1C2C3C4N(C=5C6=CC=CC=5)C(=O)CC3OCC=C2CN2C1C46CC2 QMGVPVSNSZLJIA-UHFFFAOYSA-N 0.000 title claims abstract description 154
- 241001279009 Strychnos toxifera Species 0.000 title claims abstract description 133
- 229960005453 strychnine Drugs 0.000 title claims abstract description 133
- 238000002360 preparation method Methods 0.000 title claims abstract description 37
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 34
- 201000008482 osteoarthritis Diseases 0.000 claims abstract description 13
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 66
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 65
- 239000010410 layer Substances 0.000 claims description 42
- 239000012074 organic phase Substances 0.000 claims description 34
- 239000011159 matrix material Substances 0.000 claims description 33
- 238000002156 mixing Methods 0.000 claims description 30
- 235000011187 glycerol Nutrition 0.000 claims description 22
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 20
- 239000011975 tartaric acid Substances 0.000 claims description 20
- 235000002906 tartaric acid Nutrition 0.000 claims description 20
- -1 NP-700 Chemical compound 0.000 claims description 18
- 239000012790 adhesive layer Substances 0.000 claims description 17
- 230000000181 anti-adherent effect Effects 0.000 claims description 17
- 239000011248 coating agent Substances 0.000 claims description 17
- 238000000576 coating method Methods 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 13
- 238000003756 stirring Methods 0.000 claims description 13
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 11
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 10
- 229910052782 aluminium Inorganic materials 0.000 claims description 10
- 239000008346 aqueous phase Substances 0.000 claims description 10
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims description 10
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 claims description 10
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 claims description 10
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims description 10
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims description 8
- 241000289690 Xenarthra Species 0.000 claims description 8
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 claims description 8
- 239000011734 sodium Substances 0.000 claims description 8
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 claims description 8
- 239000000243 solution Substances 0.000 claims description 8
- 229920003082 Povidone K 90 Polymers 0.000 claims description 7
- 239000007864 aqueous solution Substances 0.000 claims description 6
- 229940124274 edetate disodium Drugs 0.000 claims description 5
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 5
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 5
- 229940068968 polysorbate 80 Drugs 0.000 claims description 5
- 229920000053 polysorbate 80 Polymers 0.000 claims description 5
- 229960001367 tartaric acid Drugs 0.000 claims description 5
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims description 4
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 4
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 4
- 229940041616 menthol Drugs 0.000 claims description 4
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 claims description 4
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 claims description 4
- 229940113124 polysorbate 60 Drugs 0.000 claims description 4
- BWZOPYPOZJBVLQ-UHFFFAOYSA-K aluminium glycinate Chemical compound O[Al+]O.NCC([O-])=O BWZOPYPOZJBVLQ-UHFFFAOYSA-K 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000000463 material Substances 0.000 abstract description 16
- 238000004132 cross linking Methods 0.000 abstract description 14
- 239000003431 cross linking reagent Substances 0.000 abstract description 12
- 239000006184 cosolvent Substances 0.000 abstract description 11
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 4
- 230000007794 irritation Effects 0.000 abstract description 4
- 230000001760 anti-analgesic effect Effects 0.000 abstract description 3
- 230000014759 maintenance of location Effects 0.000 abstract description 3
- 238000011068 loading method Methods 0.000 abstract description 2
- 210000004400 mucous membrane Anatomy 0.000 abstract description 2
- 239000000825 pharmaceutical preparation Substances 0.000 abstract description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract description 2
- 238000009423 ventilation Methods 0.000 abstract description 2
- 239000004909 Moisturizer Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001333 moisturizer Effects 0.000 abstract 1
- 201000003068 rheumatic fever Diseases 0.000 abstract 1
- 239000000499 gel Substances 0.000 description 57
- 238000000034 method Methods 0.000 description 38
- 229960004063 propylene glycol Drugs 0.000 description 19
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 15
- 241000700159 Rattus Species 0.000 description 13
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 238000012360 testing method Methods 0.000 description 11
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 10
- 239000003906 humectant Substances 0.000 description 10
- 239000000203 mixture Substances 0.000 description 9
- 239000004743 Polypropylene Substances 0.000 description 8
- 210000000845 cartilage Anatomy 0.000 description 8
- 229960002390 flurbiprofen Drugs 0.000 description 8
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 239000004745 nonwoven fabric Substances 0.000 description 8
- 239000011505 plaster Substances 0.000 description 8
- 229920001155 polypropylene Polymers 0.000 description 8
- 239000005995 Aluminium silicate Substances 0.000 description 7
- 235000012211 aluminium silicate Nutrition 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 7
- 230000036407 pain Effects 0.000 description 7
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 6
- 239000003963 antioxidant agent Substances 0.000 description 6
- 230000003078 antioxidant effect Effects 0.000 description 6
- 235000006708 antioxidants Nutrition 0.000 description 6
- 210000001188 articular cartilage Anatomy 0.000 description 6
- 238000004090 dissolution Methods 0.000 description 6
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 229920002125 Sokalan® Polymers 0.000 description 5
- 235000019441 ethanol Nutrition 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 159000000000 sodium salts Chemical class 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000004408 titanium dioxide Substances 0.000 description 5
- 229920000858 Cyclodextrin Polymers 0.000 description 4
- 208000008558 Osteophyte Diseases 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 206010003246 arthritis Diseases 0.000 description 4
- 230000003542 behavioural effect Effects 0.000 description 4
- RRKTZKIUPZVBMF-IBTVXLQLSA-N brucine Chemical compound O([C@@H]1[C@H]([C@H]2C3)[C@@H]4N(C(C1)=O)C=1C=C(C(=CC=11)OC)OC)CC=C2CN2[C@@H]3[C@]41CC2 RRKTZKIUPZVBMF-IBTVXLQLSA-N 0.000 description 4
- RRKTZKIUPZVBMF-UHFFFAOYSA-N brucine Natural products C1=2C=C(OC)C(OC)=CC=2N(C(C2)=O)C3C(C4C5)C2OCC=C4CN2C5C31CC2 RRKTZKIUPZVBMF-UHFFFAOYSA-N 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 201000010934 exostosis Diseases 0.000 description 4
- 239000000945 filler Substances 0.000 description 4
- 210000000629 knee joint Anatomy 0.000 description 4
- 239000004584 polyacrylic acid Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 208000003947 Knee Osteoarthritis Diseases 0.000 description 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 3
- 208000000114 Pain Threshold Diseases 0.000 description 3
- 208000034189 Sclerosis Diseases 0.000 description 3
- 244000107975 Strychnos nux-vomica Species 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 229960001484 edetic acid Drugs 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 229960000905 indomethacin Drugs 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- 230000037040 pain threshold Effects 0.000 description 3
- 230000003285 pharmacodynamic effect Effects 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 235000010413 sodium alginate Nutrition 0.000 description 3
- 239000000661 sodium alginate Substances 0.000 description 3
- 229940005550 sodium alginate Drugs 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 239000001116 FEMA 4028 Substances 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 108090000526 Papain Proteins 0.000 description 2
- 208000031481 Pathologic Constriction Diseases 0.000 description 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 2
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 2
- 229960004853 betadex Drugs 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 210000001612 chondrocyte Anatomy 0.000 description 2
- 239000004927 clay Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 239000012738 dissolution medium Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229940014259 gelatin Drugs 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 229940055729 papain Drugs 0.000 description 2
- 235000019834 papain Nutrition 0.000 description 2
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 2
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 229910021487 silica fume Inorganic materials 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 230000036262 stenosis Effects 0.000 description 2
- 208000037804 stenosis Diseases 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- NSENZNPLAVRFMJ-UHFFFAOYSA-N 2,3-dibutylphenol Chemical compound CCCCC1=CC=CC(O)=C1CCCC NSENZNPLAVRFMJ-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 206010070918 Bone deformity Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010023232 Joint swelling Diseases 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 235000000072 L-ascorbyl-6-palmitate Nutrition 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 206010058667 Oral toxicity Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920003081 Povidone K 30 Polymers 0.000 description 1
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 description 1
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940101006 anhydrous sodium sulfite Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229940067596 butylparaben Drugs 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 description 1
- 108010085662 ecarin Proteins 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- OTGHWLKHGCENJV-UHFFFAOYSA-N glycidic acid Chemical compound OC(=O)C1CO1 OTGHWLKHGCENJV-UHFFFAOYSA-N 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 231100000418 oral toxicity Toxicity 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 229920006255 plastic film Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940001607 sodium bisulfite Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 229940001474 sodium thiosulfate Drugs 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000005065 subchondral bone plate Anatomy 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明属于药物制剂领域,具体涉及一种马钱子碱凝胶贴膏剂及其制备方法。本发明提供一种马钱子碱凝胶贴膏剂,按重量百分比计算,该贴膏剂包括0.3%‑2%的马钱子碱,3%‑10%骨架材料,20%‑50%保湿剂和助溶剂,0.1%‑2%的交联剂与交联调节剂,余量为水,以及背衬层,防粘层。使用简单的药用辅料,不使用透皮促进剂,皮肤相容性好,保湿透气,对皮肤和粘膜无刺激性,载药量大,可反复贴敷。本发明马钱子碱凝胶贴膏剂用于治疗或改善骨关节炎、风湿性关节炎,类风湿性关节炎等相关需要抗炎镇痛的疾病。
Description
技术领域
本发明属于药物制剂领域,具体涉及一种马钱子碱凝胶贴膏剂及其制备方法和用途。
背景技术
骨关节炎(OA)是一种关节退行性疾病,临床表现为关节疼痛、肿胀、僵硬等症状。关节炎是以关节肿痛为主要症状,骨关节炎最重要的病理学特征是关节软骨受损。马钱子性苦,温;有大毒。具有通络止痛,散结消肿的功效。用于跌打损伤,骨折肿痛,风湿顽痹,麻木瘫痪等。马钱子药材散结、消肿、通络、止痛,治疗关节炎已有上千年的历史,临床多为复方应用。马钱子的主要有效成分是总生物碱,其包括马钱子碱、士的宁、番木鳖次碱、马钱子新碱、番木鳖甙、依卡精等;马钱子碱是中药材马钱子治疗关节炎的药效成分。现代药理学研究证明,马钱子碱不仅具有抗炎镇痛活性,还能够促进软骨细胞增殖和抑制软骨细胞早期凋亡。士的宁基本无抗炎、镇痛作用,并且,士的宁是马钱子的主要毒性成分。
已上市的含马钱子碱相关制剂,全部为复方,由于含有士的宁,治疗窗口窄。目前,还没有马钱子碱单体相关制剂上市。
马钱子碱的油水分配系数(logP)在1-2之间,经皮吸收较好,目前已有现有技术将马钱子碱开发成外用复方制剂,比如凝胶剂、凝胶贴剂、使用压敏胶的贴剂等,但都需要在处方中加入具有强促渗作用的氮酮等透皮促进剂以提高活性成分的透皮效果。氮酮有极强的皮肤促渗作用,但由于氮酮具有高亲脂性,长期使用会在皮肤中长期蓄积,破坏角质层,导致不可逆的皮肤损伤,具有强刺激性。
本发明提供一种马钱子碱凝胶贴膏剂及其制备方法,不需要使用透皮促进剂就有很好的透皮吸收效果,用于骨关节炎、风湿性关节炎治疗,可以大幅度提高临床应用的安全性。
发明内容
本发明的目的就是针对现有技术存在的缺陷,提供一种安全、缓释、透皮效果优异的新型马钱子碱凝胶贴膏剂及其制备方法和用途。且本发明提供的马钱子碱凝胶贴膏剂,经药效试验表明具有良好的抗炎镇痛效果,制备工艺简单、可操作性强,可实现工业化生产。
本发明的第一个方面在于提供一种马钱子碱凝胶贴膏剂,按重量百分比计算,该贴膏剂包括0.3%-2%的马钱子碱,3%-10%骨架材料,20%-50%保湿剂和助溶剂,0.1%-2%的交联剂与交联调节剂,余量为水,以及背衬层,防粘层。
优选地,所述马钱子碱凝胶贴膏剂,按重量百分比计算,该贴膏剂包含0.3%-1%的马钱子碱,4%-8%骨架材料,25%-40%保湿剂和助溶剂,0.3%-1%的交联剂与交联调节剂,余量为水,以及背衬层,防粘层。
所述马钱子碱凝胶贴膏剂中,所述骨架材料选自卡波姆、海藻酸钠、阿拉伯胶、西黄芪胶、明胶、淀粉、黄原胶、聚丙烯酸(钠)、聚乙烯醇、聚维酮K90、聚维酮K30、羧甲基纤维素钠、聚乙烯吡咯烷酮、HPMC、海藻酸及其钠盐、聚丙烯酸交联树脂、聚丙烯酸部分中和物(NP-600、NP-700、NP-800)中的一种或多种的组合;优选地,所述骨架材料选自聚丙烯酸部分中和物(NP-600、NP-700、NP-800)、聚丙烯酸钠、聚维酮K90、羧甲基纤维素钠中的一种或多种。
所述马钱子碱凝胶贴膏剂中,所述保湿剂和助溶剂选自乙醇、尿素、橄榄油、聚山梨酯80、聚山梨酯60、丙二醇、甘油、DMSO、二乙二醇单乙醚、聚乙二醇400、桉叶油、环糊精、山梨醇中的一种或多种的组合;优选地,所述保湿剂和助溶剂选自甘油、丙二醇、DMSO、聚山梨酯80、聚乙二醇400和环糊精中的一种或两种或多种的组合。
所述马钱子碱凝胶贴膏剂中,所述交联剂与交联调节剂选自氢氧化铝、甘羟铝、三氯化铝、硫酸铝、明矾、复合铝盐、酒石酸、柠檬酸、苹果酸、依地酸及其钠盐中的一种或多种的组合;优选地,所述交联剂与交联调节剂选自甘羟铝、氢氧化铝、酒石酸、柠檬酸、依地酸及其钠盐中的一种或多种的组合。
所述马钱子碱凝胶贴膏剂中,所述背衬层选自本领域人员公知的材料,如无纺布、人造棉布等。
所述马钱子碱凝胶贴膏剂中,所述防粘层选自本领域人员公知的材料,如聚丙烯压花膜、聚乙烯膜、防黏纸、塑料薄膜、硬质纱布等。
本发明第一个方面的一些实施方式中,所述马钱子碱凝胶贴膏剂按重量百分比计算还可以包含0.05%-0.075%抗氧剂;所述抗氧剂选自无水亚硫酸钠、焦亚硫酸钠、亚硫酸氢钠、硫代硫酸钠、叔丁基对羟基茴香醚、二丁基苯酚、维生素C、维生素C棕榈酸酯、依地酸及其钠盐中的一种或多种的组合;
所述马钱子碱凝胶贴膏剂按重量百分比计算还可以包含0.01%-0.3%抑菌剂,优选0.1%-0.2%抑菌剂;所述抑菌剂选自三氯叔丁醇、羟苯乙酯、苯甲醇、羟苯甲酯、羟苯丁酯、山梨酸及其钾盐、薄荷脑、苯甲酸及其钠盐中的一种或多种的组合;
所述马钱子碱凝胶贴膏剂按重量百分比计算还可以包含0.1-10%填充剂;优选0.1-5%填充剂;所述填充剂选自高岭土、硅藻土、皂土、氧化锌、二氧化钛、微粉硅胶中的一种或多种的组合;优选地,所述填充剂选自高岭土、二氧化钛、微粉硅胶中的一种或多种的组合;
本发明提供一种马钱子碱凝胶贴膏剂的制备方法,可使用方法一至方法三中的任一种方法制备。
方法一:包括以下步骤:(1)制备空白基质包含保湿剂与助溶剂、抑菌剂、骨架材料、交联剂与交联调节剂、抗氧剂以及处方量的水;(2)将马钱子碱溶于助溶剂中与空白基质混合得到马钱子碱膏体;(3)马钱子碱膏体涂布于背衬层上,附上防粘层得到马钱子碱凝胶贴膏剂。
方法二:包括以下步骤:(1)制备马钱子碱有机相,包含保湿剂与助溶剂、马钱子碱、抑菌剂、骨架材料、交联剂与交联调节剂、抗氧剂;(2)制备水相基质,包含交联剂与交联调节剂和水;(3)马钱子碱有机相与水相基质混合得到马钱子碱膏体;(4)马钱子碱膏体涂布于背衬层上,附上防粘层得到马钱子碱凝胶贴膏剂。
方法三:包括以下步骤:(1)制备有机相基质,包含保湿剂、抑菌剂、骨架材料、交联剂与交联调节剂、抗氧剂;(2)制备马钱子碱水相,包含马钱子碱、交联剂与交联调节剂、助溶剂与水;(3)有机相基质与马钱子碱水相混合得到马钱子碱膏体;(4)马钱子碱膏体涂布于背衬层上,附上防粘层得到马钱子碱凝胶贴膏剂。
方法四:包括如下步骤:
(1)制备有机相基质,包含保湿剂、骨架材料、交联剂与交联调节剂;(2)制备马钱子碱水相,包含马钱子碱、交联调节剂与水;(3)有机相基质与马钱子碱水相混合得到马钱子碱膏体;(4)马钱子碱膏体涂布于背衬层上,附上防粘层得到马钱子碱凝胶贴膏剂;步骤(1)有机相基质还任选包含抑菌剂、抗氧剂。
上述方法中所有辅料按照处方量及种类实际情况进行调整。
本发明提供一种马钱子碱凝胶贴膏剂在制备用于膝骨关节炎的药物中的应用。
本发明中,如无特别说明,其中:
术语“空白基质”是指除马钱子碱膏体中除马钱子碱以外的一切组成。
术语“有机相”是指与水不相溶的,以有机化合物为主体的部分。
术语“水相”是指水为主体的部分。
术语“骨架材料”是指有产品的骨架支撑,药物储库,产生粘性,保水保湿作用的物质。
术语“助溶剂”是指有助于主药溶解及释放的物质。
术语“保湿剂”是指在于延缓水份丢失、提高产品稳定性的物质。
术语“交联剂”是指使产品具有微观立体结构,提高产品稳定性的物质。
术语“交联调节剂”是指提高产品稳定性,使药物处于最佳溶出状态的物质。
与现有技术相比,本发明具有以下有益效果:
1、马钱子碱口服治疗关节炎毒副作用大,开发马钱子碱局部外用贴膏剂,避免了口服毒性,提高药物的生物利用度,提高治疗效果。
2、制备得到的马钱子碱凝胶贴膏剂,使用简单的药用辅料,不使用氮酮等具有强刺激性的透皮促进剂,但透皮效果优异,皮肤相容性好,保湿透气,对皮肤和粘膜无刺激性,载药量大,可反复贴敷。
具体实施方式
下面将结合实施例对本发明的实施方案进行详细描述,但本领域技术人员将会理解,下列实施例仅用于说明本发明,而不应视为限定本发明的范围。实施例中未注明具体条件者,按照常规条件或制造商建议的条件进行。所用试剂或仪器未注明生产厂商者,均为可以通过市购获得的常规产品。本发明发明人经过大量创造性的劳动,进行处方工艺筛选过程,获得了本发明的技术方案。
处方筛选预实验
通过大量的处方筛选及工艺研究,确定本发明的最优的处方及工艺。部分处方筛选过程见表1。
表1马钱子碱凝胶贴膏处方工艺筛选过程
处方中余量以水补足,以上处方说明用CMC-Na或明胶等代替聚丙烯酸钠部分中和物所得的膏体性状不稳定,而以聚丙烯酸钠部分中和物、交联剂与交联调节剂为主,配以适宜的助溶剂、保湿剂和其余的骨架材料可得到性状稳定的凝胶贴膏。而制备方法可根据辅料的种类选择适宜的制备方法,三种方法所得凝胶贴膏性状均稳定、良好。
实施例1
配方 | 用量(g) |
马钱子碱 | 6 |
甘油 | 400 |
丙二醇 | 160 |
NP-700 | 120 |
甘羟铝 | 6 |
羟苯乙酯 | 2 |
依地酸二钠 | 4 |
酒石酸 | 6 |
水 | 1296 |
背衬层 | 无纺布 |
防粘层 | 聚丙烯压花膜 |
制备方法:
(1)将羟苯乙酯溶于丙二醇后加入甘油、NP-700、依地酸二钠、甘羟铝混匀,得到有机相基质;(2)将酒石酸、水、马钱子碱混匀溶解,得到马钱子碱水相,加入有机相基质中搅拌均匀,制得马钱子碱膏体;(3)马钱子碱膏体涂布于背衬层上,附上防粘层得到马钱子碱凝胶贴膏剂。
实施例2
配方 | 用量(g) |
马钱子碱 | 12 |
甘油 | 400 |
丙二醇 | 100 |
乙醇 | 100 |
NP-600 | 60 |
CMC-Na | 60 |
甘羟铝 | 6 |
酒石酸 | 6 |
薄荷脑 | 20 |
依地酸二钠 | 4 |
水 | 1232 |
背衬层 | 无纺布 |
防粘层 | 聚丙烯压花膜 |
制备方法:
(1)将薄荷脑溶于乙醇后,加入丙二醇、甘油、NP-600、CMC-Na、依地酸二钠、甘羟铝混匀,得到有机相基质;(2)将马钱子碱、酒石酸、水混匀溶解,得到马钱子碱溶液,加入有机相基质中搅拌均匀,制得马钱子碱膏体;(3)马钱子碱膏体涂布于背衬层上,附上防粘层得到马钱子碱凝胶贴膏剂。
实施例3
配方 | 用量(g) |
马钱子碱 | 12 |
甘油 | 400 |
丙二醇 | 100 |
乙醇 | 100 |
PEG400 | 100 |
聚丙烯酸钠 | 140 |
甘羟铝 | 6 |
酒石酸 | 10 |
依地酸二钠 | 4 |
水 | 1128 |
背衬层 | 无纺布 |
防粘层 | 聚丙烯压花膜 |
制备方法:
(1)将马钱子碱溶于PEG400、乙醇的混合溶液,加入丙二醇、甘油、聚丙烯酸钠、依地酸二钠、甘羟铝混匀,得到马钱子碱有机相;(2)将酒石酸、水混匀溶解,得到水相溶液,加入马钱子碱有机相中搅拌均匀,制得马钱子碱膏体;(3)马钱子碱膏体涂布于背衬层上,附上防粘层得到马钱子碱凝胶贴膏剂。
实施例4
制备方法:
(1)将马钱子碱溶于DMSO后,加入丙二醇、甘油、NP-800、CMC-Na、高岭土、依地酸二钠、甘羟铝混匀,得到马钱子碱有机相;(2)将酒石酸、水混匀溶解,得到水相溶液,加入马钱子碱有机相中搅拌均匀,制得马钱子碱膏体;(3)马钱子碱膏体涂布于背衬层上,附上防粘层得到马钱子碱凝胶贴膏剂。
实施例5
配方 | 用量(g) |
马钱子碱 | 12 |
NP-700 | 80 |
甘油 | 400 |
丙二醇 | 100 |
羟苯乙酯 | 1.6 |
聚维酮K90 | 50 |
甘羟铝 | 6 |
酒石酸 | 6 |
依地酸二钠 | 6 |
聚山梨酯80 | 60 |
水 | 1278.4 |
背衬层 | 无纺布 |
防粘层 | 聚丙烯压花膜 |
制备方法:
(1)将羟苯乙酯溶于丙二醇后,加入甘油、NP-700、依地酸二钠、甘羟铝、聚维酮K90混匀,得到有机相基质;(2)将马钱子碱、酒石酸、聚山梨酯80、水混匀溶解,得到马钱子水相溶液,加入有机相基质中搅拌均匀,制得马钱子碱膏体;(3)马钱子碱膏体涂布于背衬层上,附上防粘层得到马钱子碱凝胶贴膏剂。
实施例6
制备方法:
(1)将羟苯乙酯溶于丙二醇,加入甘油、桉叶油、NP-700、依地酸二钠、氢氧化铝、聚乙烯醇混匀,得到有机相基质;(2)将马钱子碱、酒石酸、水混匀溶解,得到马钱子碱水相溶液,加入有机相基质中搅拌均匀,制得马钱子碱膏体;(3)马钱子碱膏体涂布于背衬层上,附上防粘层得到马钱子碱凝胶贴膏剂。
实施例7
配方 | 用量(g) |
马钱子碱 | 24 |
甘油 | 400 |
丙二醇 | 160 |
聚丙烯酸钠 | 80 |
甘羟铝 | 6 |
羟苯乙酯 | 2 |
依地酸二钠 | 4 |
酒石酸 | 6 |
HPMC | 80 |
聚山梨酯60 | 100 |
水 | 1138 |
背衬层 | 无纺布 |
防粘层 | 聚丙烯压花膜 |
制备方法:
(1)将羟苯乙酯溶于丙二醇,加入甘油、聚丙烯酸钠、依地酸二钠、HPMC、甘羟铝混匀,得到得到有机相基质;(2)将马钱子碱、酒石酸、聚山梨酯60、水混匀溶解,得到马钱子碱水相溶液,加入有机相基质中搅拌均匀,制得马钱子碱膏体;(3)马钱子碱膏体涂布于背衬层上,附上防粘层得到马钱子碱凝胶贴膏剂。
实施例8
配方 | 用量(g) |
马钱子碱 | 10 |
甘油 | 400 |
DMSO | 160 |
丙二醇 | 100 |
NP-800 | 60 |
甘羟铝 | 6 |
羟苯乙酯 | 2 |
依地酸二钠 | 4 |
酒石酸 | 6 |
聚维酮K90 | 60 |
高岭土 | 60 |
β-环糊精 | 40 |
水 | 1092 |
背衬层 | 无纺布 |
防粘层 | 聚丙烯压花膜 |
制备方法:
(1)将羟苯乙酯溶于丙二醇,加入DMSO、甘油、NP-800、聚维酮K90、高岭土、甘羟铝、依地酸二钠混匀,得到有机相基质;(2)将马钱子碱、酒石酸、β-环糊精、水混匀溶解,得到马钱子碱水相溶液,加入有机相基质中搅拌均匀,制得马钱子碱膏体;(3)马钱子碱膏体涂布于背衬层上,附上防粘层得到马钱子碱凝胶贴膏剂。
实施例9
制备方法:
(1)将羟苯乙酯溶于丙二醇,加入甘油、NP-700、依地酸二钠、甘羟铝、微粉硅胶、二氧化钛混匀,得到有机相基质;(2)将马钱子碱、酒石酸、尿素、水混匀溶解,得到马钱子碱水相溶液,加入有机相基质中搅拌均匀,制得马钱子碱膏体;(3)马钱子碱膏体涂布于背衬层上,附上防粘层得到马钱子碱凝胶贴膏剂。
实施例10
配方 | 用量(g) |
马钱子碱 | 12 |
甘油 | 400 |
丙二醇 | 160 |
油酸 | 50 |
NP-600 | 80 |
甘羟铝 | 10 |
羟苯乙酯 | 2 |
依地酸二钠 | 4 |
柠檬酸 | 6 |
CMC-Na | 60 |
海藻酸钠 | 100 |
高岭土 | 60 |
二氧化钛 | 2 |
水 | 1054 |
背衬层 | 无纺布 |
防粘层 | 聚丙烯压花膜 |
制备方法:
将羟苯乙酯溶于丙二醇,加入甘油、油酸、NP-600、CMC-Na、海藻酸钠、高岭土、依地酸二钠、二氧化钛、甘羟铝混匀,得到有机相基质;(2)将马钱子碱、柠檬酸、水混匀,得到马钱子水相溶液,加入有机相基质中搅拌均匀,制得马钱子碱膏体;(3)马钱子碱膏体涂布于背衬层上,附上防粘层得到马钱子碱凝胶贴膏剂。
试验例1:本发明马钱子碱凝胶贴膏制剂的性状研究
对根据实施例1-10的凝胶贴膏制剂进行物理性状的肉眼观察,可知其外观平整光滑、均匀;成型性、初黏力以及膜残留量均符合要求。
试验例2:本发明马钱子碱凝胶贴膏制剂释放度研究
采用浆碟法,根据《中国药典》2015第四部通则0931溶出度与释放度测定法第四法浆碟法第二法,具体方法为:
分别量取溶出介质(4%氯化钠溶液)900ml于溶出杯内,预温至32℃±0.5℃,将实施例1、实施例2、实施例3、实施例4、实施例5、实施例6、实施例7、实施例8、实施例9、实施例10固定于网碟上,溶出面朝上,尽可能使其保持平整。再将网碟水平放置于溶出杯下部,并使网碟与浆底旋转面平行,两者相距25mm±2mm,50转/分钟,定时取样,吸取溶出液适量,及时补充相同体积的温度为32℃±0.5℃的溶出介质。结果见下表2:
表2马钱子碱凝胶贴膏释放度实验结果
时间(h) | 0 | 0.5 | 1 | 3 | 5 | 8 |
实施例1(%) | 0 | 26.39 | 38.07 | 65.78 | 80.14 | 90.52 |
实施例2(%) | 0 | 40.33 | 56.84 | 86.35 | 96.31 | 100.53 |
实施例3(%) | 0 | 35.17 | 43.23 | 73.96 | 84.87 | 98.05 |
实施例4(%) | 0 | 42.11 | 54.49 | 84.87 | 95.97 | 99.78 |
实施例5(%) | 0 | 43.21 | 60.57 | 88.17 | 98.39 | 100.04 |
实施例6(%) | 0 | 42.43 | 55.02 | 86.84 | 95.29 | 99.86 |
实施例7(%) | 0 | 41.67 | 58.09 | 87.14 | 95.68 | 100.63 |
实施例8(%) | 0 | 38.07 | 57.78 | 87.02 | 95.54 | 100.02 |
实施例9(%) | 0 | 43.57 | 59.08 | 87.29 | 94.09 | 100.35 |
实施例10(%) | 0 | 25.93 | 37.29 | 68.74 | 82.16 | 93.04 |
本发明提供的马钱子碱凝胶贴膏剂,在进行体外释放度实验时,除实施例1和实施例10与其他实施例相比稍微缓慢外,其余实施例释放度无明显差异,本发明所有实施例8小时累计释放结果均大于90%,具有良好效果。
试验例3:本发明马钱子碱凝胶贴膏制剂释体外释放研究
采用Franz扩散池法,以离体大鼠腹部皮肤为屏障,试验样品为实施例2、实施例4、实施例5、实施例6、实施例7、实施例8、实施例9和对比组市售吲哚美辛巴布膏(生产厂家:尼普洛药品株式会社,进口药品注册证号H20181060),具体方法为:
将大鼠脱颈椎处死,将腹部及周边的毛用剃毛刀脱干净,用解剖剪将褪毛部分的大鼠皮整块剥离,清洗干净后自然固定在改良的Franz扩散池上,使皮肤表面面向供药室,皮肤里层与接受液刚好接触,将揭去防粘层的凝胶贴膏贴于皮肤表面上,接受液为37℃预热的pH=7.4的PBS缓冲液。接受室水浴温度为37℃,磁力搅拌转速为500rpm。分别于1、2、4、6、8、24h取样,将接受液全部取出,并补加等量新鲜接受液。结果见下表3:
表3马钱子碱凝胶贴膏体外透皮实验结果
时间(h) | 0 | 1 | 2 | 4 | 6 | 8 | 24 |
实施例2(μg) | 0 | 0.78 | 2.15 | 6.38 | 10.45 | 14.89 | 76.37 |
实施例4(μg) | 0 | 0.19 | 0.56 | 2.01 | 3.42 | 5.68 | 49.15 |
实施例5(μg) | 0 | 0.21 | 0.78 | 3.52 | 6.89 | 15.25 | 80.02 |
实施例6(μg) | 0 | 0.23 | 0.56 | 3.08 | 6.56 | 12.74 | 55.81 |
实施例7(μg) | 0 | 0.20 | 0.77 | 3.19 | 6.78 | 14.15 | 70.61 |
实施例8(μg) | 0 | 0.19 | 0.69 | 2.77 | 5.89 | 10.96 | 52.63 |
实施例9(μg) | 0 | 0.10 | 0.63 | 2.98 | 6.32 | 11.05 | 56.62 |
对比例(市售吲哚美辛巴布膏) | 0 | 0.27 | 0.74 | 1.98 | 3.48 | 5.33 | 32.36 |
本发明提供的马钱子碱凝胶贴膏剂,没有使用强促渗作用的氮酮等透皮促进剂来提高活性成分的透皮效果。而对比例市售吲哚美辛巴布膏中含有氮酮,在进行体外透皮实验时,试验结果表明本发明实施例24小时的累计透皮质量均高于对比组药物。
试验例4药效试验
通过骨关节炎药效预试验对表3处方进行了筛选研究,实施例2,实例5,实施例7具有较好的治疗骨关节药效。因此对实施例2,实例5,实施例7进行了正式骨关节炎药效学研究,具体试验方法及结果如下:
4.1实验动物与药物
4.1.1实验动物和药物
SD大鼠,SPF级(无特定病原体级实验动物):体重210-220g,全雄,购自斯贝福(北京)生物技术有限公司;
4.1.2药物
木瓜蛋白酶:716M022,Solarbio
氟比洛芬凝胶贴膏,生产企业:MIKASA SEIYAKU CO.,LTD KAKEGAWA FACTORY,分装企业:北京泰德制药股份有限公司。批号:103023-01,
L-半胱胺酸:WXBD0897V,SIGMA
4.2实验方法
4.2.1组别设置
本试验共设6组,分别为正常对照组、模型组、氟比洛芬凝胶贴膏组(阳性药组)、实施例2,实施例5,实施例7,每组10只大鼠。正常对照组、模型组均膝关节敷贴马钱子碱凝胶贴剂制剂空白。
4.2.2给药周期
连续给药14天,每天1次。
4.2.3造模
造模部位为右侧膝关节,单侧造模。
大鼠关节腔注射4%木瓜蛋白酶、0.03mol/L L-半胱胺酸(体积2:1混合)造模。
4.3实验结果
行为学评价结果显示,与模型组比较,实施例组和氟比洛芬凝胶贴膏组行为学评分均显著降低(p<0.01、p<0.05),均可减轻大鼠不适,从而改善大鼠走路踮脚行为。
X光片结果显示,与模型组比较,实施例组和氟比洛芬凝胶贴膏组X光评分显著降低(p<0.001、p<0.01、p<0.05),均可显著减轻模型大鼠膝关节关节腔狭窄、骨赘及骨质硬化等退行性病变,对膝骨关节炎有显著的治疗作用。
痛阈结果显示,与模型组比较,实施例组和氟比洛芬凝胶贴膏组,痛阈显著升高(p<0.001),均可显著镇痛。
关节软骨大体观察评分结果显示,与模型组比较,实施例组和氟比洛芬凝胶贴膏组关节软骨大体观察评分显著降低(p<0.01、p<0.05),均有保护软骨的作用。
组织病理学镜下检查结果显示,与模型组比较,实施例组均可见明显延缓病变进展,氟比洛芬凝胶贴膏组延缓病变进展无明显变化。
实验数据结果见下表。
马钱子碱凝胶贴膏治疗大鼠膝骨关节炎药效学试验结果
注:与对照组比较:###p<0.001,#p<0.05;与模型组比较:**p<0.01,*p<0.05。
行为学评分、X光片评分、痛阈以及关节软骨大体观察评分的评价标准如下:
(1)行为学评分
测定时间:分组前、给药结束。
测定方法:让大鼠在长1米,A4纸宽的跑道上跑,两个后脚丫涂印泥。然后根据模型脚丫印泥占整个脚丫的量评分。
评分标准:0分:左右脚掌印泥颜色一致;
1分:左脚掌<25%颜色深于右脚掌;
2分:左脚掌25-50%颜色深于右脚掌;
3分:左脚掌50-75%颜色深于右脚掌;
4分:左脚掌>75%颜色深于右脚掌。
(2)X光片评分
测定时间:分组前、给药结束。
测定方法:采用高频X射线机测定。按K-L分级系统进行评估。
评分标准:0分:无改变;
1分:见可疑的关节腔狭窄(JSN)和唇样增生;
2分:见明确的骨赘(OP)形成及可能的JSN;
3分:见明确的JSN、骨质硬化及可能的形态改变;
4分:见较大的OP、明确的JSN、严重骨质硬化、骨畸形。
(3)机械痛值测定
测定时间:给药结束。
测定方法:VonFrey疼痛法。
(4)关节软骨的大体观察
测定时间:试验结束。
测定方法:大鼠安乐死后,观察膝关节及软骨,进行Pelletier评分。
评分标准:0分:关节面光整,色泽如常;
1分:关节面粗糙,有小的裂隙且色泽灰暗;
2分:软骨缺损深达软骨中层;
3分:软骨面溃疡形成,软骨缺损深达软骨深层;
4分:软骨剥脱,软骨下骨质裸露。
Claims (4)
1.一种马钱子碱凝胶贴膏剂,其特征在于,所述马钱子碱凝胶贴膏剂配方如下:
所述马钱子碱凝胶贴膏剂制备方法如下:
(1)将薄荷脑溶于乙醇后,加入丙二醇、甘油、NP-600、CMC-Na、依地酸二钠、甘羟铝混匀,得到有机相基质;(2)将马钱子碱、酒石酸、水混匀溶解,得到马钱子碱溶液,加入有机相基质中搅拌均匀,制得马钱子碱膏体;(3)马钱子碱膏体涂布于背衬层上,附上防粘层得到马钱子碱凝胶贴膏剂。
2.一种马钱子碱凝胶贴膏剂,其特征在于,所述马钱子碱凝胶贴膏剂配方如下:
所述马钱子碱凝胶贴膏剂制备方法如下:
(1)将羟苯乙酯溶于丙二醇后,加入甘油、NP-700、依地酸二钠、甘羟铝、聚维酮K90混匀,得到有机相基质;(2)将马钱子碱、酒石酸、聚山梨酯80、水混匀溶解,得到马钱子水相溶液,加入有机相基质中搅拌均匀,制得马钱子碱膏体;(3)马钱子碱膏体涂布于背衬层上,附上防粘层得到马钱子碱凝胶贴膏剂。
3.一种马钱子碱凝胶贴膏剂,其特征在于,所述马钱子碱凝胶贴膏剂配方如下:
所述马钱子碱凝胶贴膏剂制备方法如下:
(1)将羟苯乙酯溶于丙二醇,加入甘油、聚丙烯酸钠、依地酸二钠、HPMC、甘羟铝混匀,得到有机相基质;(2)将马钱子碱、酒石酸、聚山梨酯60、水混匀溶解,得到马钱子碱水相溶液,加入有机相基质中搅拌均匀,制得马钱子碱膏体;(3)马钱子碱膏体涂布于背衬层上,附上防粘层得到马钱子碱凝胶贴膏剂。
4.权利要求1-3任一项所述的马钱子碱凝胶贴膏剂在制备用于治疗或改善骨关节炎药物中的应用。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011305433X | 2020-11-20 | ||
CN202011305433 | 2020-11-20 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114533701A CN114533701A (zh) | 2022-05-27 |
CN114533701B true CN114533701B (zh) | 2023-12-22 |
Family
ID=81668481
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111376621.6A Active CN114533701B (zh) | 2020-11-20 | 2021-11-19 | 一种马钱子碱凝胶贴膏剂及其制备方法和用途 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20240100042A1 (zh) |
EP (1) | EP4248953A4 (zh) |
JP (1) | JP2023551417A (zh) |
CN (1) | CN114533701B (zh) |
WO (1) | WO2022105891A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114624352A (zh) * | 2021-06-30 | 2022-06-14 | 海南赛立克药业有限公司 | 一种马钱子碱贴膏剂的含量及有关物质检测方法和用途 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104997981A (zh) * | 2015-07-27 | 2015-10-28 | 江苏七O七天然制药有限公司 | 一种治疗局部风湿性疼痛综合症的中药凝胶膏及其制备方法 |
KR20180042707A (ko) * | 2016-10-18 | 2018-04-26 | 주식회사 엘지생활건강 | 스트리크닌을 포함하는 화장료 조성물 |
CN108117557A (zh) * | 2016-11-28 | 2018-06-05 | 北京盈科瑞创新医药股份有限公司 | 一种马钱子碱的提取分离纯化方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100594027C (zh) * | 2001-12-05 | 2010-03-17 | 张喜田 | 番木鳖碱、马钱子碱和一叶秋碱及其盐的透皮剂 |
CN103027948B (zh) * | 2011-09-30 | 2015-03-11 | 北京因科瑞斯医药科技有限公司 | 马钱子总碱的提取分离方法 |
CN112386565A (zh) * | 2019-08-02 | 2021-02-23 | 北京盈科瑞创新医药股份有限公司 | 一种马钱子碱凝胶制剂及其制备方法 |
-
2021
- 2021-11-19 EP EP21894038.5A patent/EP4248953A4/en active Pending
- 2021-11-19 US US18/253,878 patent/US20240100042A1/en active Pending
- 2021-11-19 JP JP2023529039A patent/JP2023551417A/ja active Pending
- 2021-11-19 WO PCT/CN2021/131901 patent/WO2022105891A1/zh active Application Filing
- 2021-11-19 CN CN202111376621.6A patent/CN114533701B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104997981A (zh) * | 2015-07-27 | 2015-10-28 | 江苏七O七天然制药有限公司 | 一种治疗局部风湿性疼痛综合症的中药凝胶膏及其制备方法 |
KR20180042707A (ko) * | 2016-10-18 | 2018-04-26 | 주식회사 엘지생활건강 | 스트리크닌을 포함하는 화장료 조성물 |
CN108117557A (zh) * | 2016-11-28 | 2018-06-05 | 北京盈科瑞创新医药股份有限公司 | 一种马钱子碱的提取分离纯化方法 |
Non-Patent Citations (4)
Title |
---|
徐金华等.马钱子碱的研究进展.《中国新药杂志》.2009,第18卷(第3期),第213-216、221页. * |
於滔.马钱子巴布剂体外透皮实验及促透剂的筛选.《中国医院药学杂志》.2018,第38卷(第3期),第229-233页. * |
蒋莹莹.马钱子生物碱组分及其透皮制剂的研究.《中国优秀硕士学位论文全文数据库 医药卫生科技辑》.2018,(第06期),E057-22. * |
马钱子体内过程及药效机制的研究进展;陈庆等;风湿病与关节炎;第4卷(第10期);57-62 * |
Also Published As
Publication number | Publication date |
---|---|
EP4248953A1 (en) | 2023-09-27 |
WO2022105891A1 (zh) | 2022-05-27 |
US20240100042A1 (en) | 2024-03-28 |
EP4248953A4 (en) | 2024-05-22 |
JP2023551417A (ja) | 2023-12-08 |
CN114533701A (zh) | 2022-05-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK175661B1 (da) | Polysaccharidestere | |
CA1218605A (en) | Pharmaceutical composition and its rectal use | |
CN102600110B (zh) | 一种氨基葡萄糖巴布剂及其制备方法和用途 | |
JP2001503062A (ja) | 透過促進剤としての乳酸の脂肪酸エステルの塩 | |
JPH06104624B2 (ja) | 経皮吸収剤 | |
JPH08505850A (ja) | 抗ウイルス局所用医薬組成物 | |
CN114533701B (zh) | 一种马钱子碱凝胶贴膏剂及其制备方法和用途 | |
HUP0402135A2 (hu) | Csontnövekedést serkentő vegyületekből készült, szabályozott hatóanyag-leadású, implantátumképző polimerkészítmények, eljárás ezek előállítására | |
WO1993009768A1 (en) | Fomentation containing ketorolac | |
WO2005113002A1 (ja) | ムスカリン受容体作動薬を含有する眼科用経皮吸収型製剤 | |
TWI468192B (zh) | 含有二克氯吩鈉(Dichlofenac sodium)之水性貼劑 | |
WO2014007597A1 (ko) | 로티고틴 함유 경피흡수제제 | |
CN102058608B (zh) | 氨基葡萄糖治疗口腔溃疡的用途 | |
CN102657602A (zh) | 3,5-二羟基-4-异丙基二苯乙烯壳聚糖凝胶剂及其制备方法 | |
US20230250199A1 (en) | Low molecular weight chondroitin sulfate, composition, preparation method and use thereof | |
US11572421B2 (en) | Low molecular weight chondroitin sulfate, composition, preparation method and use thereof | |
JPH0818983B2 (ja) | 水虫治療剤 | |
CN111789832B (zh) | 右酮洛芬氨丁三醇凝胶贴膏及其制备方法 | |
Ahuja et al. | Formulation and evaluation of diclofenac sodium gel by using natural polymer | |
Khokhlenkova | Prospects of using biopolymeric films in medicine and pharmacy | |
RU2178693C2 (ru) | Противовирусное средство для наружного применения на основе гиалуроновой кислоты | |
CN107281094B (zh) | 一种马来酸噻吗洛尔药用组合物及其制备方法 | |
AR023840A2 (es) | Forma polimerica cristalina 2 del compuesto acetato de metil -n3-[2-{3-4-(formamidinofenil)-isoxazolin-5(r)-il}-acetil]-n2-(n-butiloxicarbonil)-2,3-(s)-diaminopropionato (roxifiban), composicion farmaceutica que lo contiene y su uso para preparar un medicamento que inhibe la union de una proteina ad | |
CN1174031A (zh) | 双氯芬酸钠透皮控释贴膏 | |
CN102295654B (zh) | 一种头孢西丁化合物及其组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20230804 Address after: 653100 Daying street, Hongta District, Yuxi City, Yunnan Province Applicant after: Sailing Pharmaceutical Technology Group Co.,Ltd. Address before: 571126 No. 6, Shunda Road, Meilan District, Haikou City, Hainan Province Applicant before: HAINAN SELECTION PHARMACEUTICAL CO.,LTD. Applicant before: Beijing Increasepharm Co.,Ltd. |
|
GR01 | Patent grant | ||
GR01 | Patent grant |